For Immediate Release
Q1 Net Revenue at Rs 648 Crores, Net Profit at Rs 65 CroresVadodara July 2ot2017
Alembic Pharmaceuticals Limited reported its consolidated financial results forthe first
h
quarter ending 301
June 2017.
Financial Highlights
Net Sales for the quarter atRs 648crores against Rs 737crores lastyear.
Net Profit for the quarter at Rs 65crores against Rs 102crores last year.
Mr.Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said "The performance in the quarter was weak primarily due to thetransit ional provision of GST on the India Branded business.Our expansion is progressing well and our Oncology facility was recently inaugurated by the Honorable Chief Minister of Gujarat, Shri Vijaybhai Rupani"
Operational Highlightsfor the quarter International Business
International formulation business revenuewas Rs 282 crores against Rs 309 crores lastyear
US formulation business revenue was Rs 211 crores for the quarter
6 ANDA approvals received during the quarter,CumulativeANDA approvals at
58
6 ANDA filings during the quarter, Cumulative ANDA filings at 101
R&D spend at Rs 94 Crores, approximately 14% of Sales.
India FormulationsBusiness
India formulations business for the quarterat Rs 236crores as against Rs 299 crores last year
ALEMBIC PHARMACEUTICALSLIMITED
REG.OFFICE :ALEBICROAD, VADODARA• 390 003.•TEL :(0265) 2280550, 2280880 •FAX :(0265) 2281229
website:www.alemb1cpharmaceuticals.com • E mail:alambic@alemblc.co.n• CIN :L24230GJ2010PLC061123
Summary of Total Revenue is as under:
(Rs in Crores)
Particulars | Q1 FY18 | Q1 FY17 |
Formulation | 282 | 309 |
International | ||
India | 236 | 299 |
API | 130 | 129 |
Total | 648 | 737 |
The Profit break-up is as under:
(Rs in Crores)
Particulars | Q1 FY18 | Q1 FY17 |
EBITDA PreR&D | 195 | 237 |
EB/TOA Pre R&D% | 30% | 32% |
EBITDAPost R&D | 105 | 157 |
EB/TOA Post R&D% | 16% | 21% |
Profit Before Tax | 79 | 137 |
Net Profit after Tax | 65 | 102 |
ALEMBIC PHARMACEUTICALS LIMITED
REGO. OFFICE :ALEMBIC ROAD,VAOODARA • 390 003. • TEL :(0265) 2280550,2280880 • FAX :(0265) 2281229
website :www.alamblcpharmaceutlcals.com •E•mail :alomblc@alembic.co. n • CIN :L24230GJ2010PLC061123
AboutAlembic PharmaceuticalsLimited
Alembic Pharmaceuticals Limited, avertically integrated research anddevelopment pharmaceuticalcompany, hasbeen atthe forefront of healthcare since 1907.Headquartered in lndia1Alembic isa publiclylisted company that manufactures andmarkets genericpharmaceutical products allover the world. Alembic's stateof the artresearch and manufacturing facilitiesare approved by regulatory authorities of manydeveloped countries including theUS FDA. Alembic isone ofthe leaders in brandedgenerics in India.Alembic's brands,marketed through a marketing teamof over 5000are well recognized by doctors and patients.
Information about the company can be found at www.alembicpharmaceuticals.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)
For more informationcontact:
Aja yKumar DesaiMitanshu Shah
Phone: +91 22 -306 11681 Phone: +91265 -3007630
Email:ajay.desai@al_ernlli c.o.i nEmail:mitanshu.shah@al emi c:_c:c,._i _n
ALEMBIC PHARMACEUTICALS LIMITED
REGO. OFFICE :ALEMBIC ROAD, ADODARA •390 003.•TEL :(0265)2280550, 2280880 • FAX ;(0285) 2281229
website :www.alemblcpharmaceut1cals.com • E mail :alemblc@alembic.co.ln •CIN:L24230GJ2010PLC061123
Alembic Pharmaceuticals Limited published this content on 20 July 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 21 July 2017 07:09:07 UTC.
Original documenthttp://www.alembicpharmaceuticals.com/wp-content/uploads/2016/Investors/Statutory-Details/Notices-Correspondences/2016-2017/Press%20Release%20April%20June,%202017.pdf
Public permalinkhttp://www.publicnow.com/view/BD293B3A909A84C519CD512FAF3AB5C456395AC8